loading page

Tranexamic acid for the prevention of postpartum hemorrhage: a cost-effectiveness analysis
  • +1
  • Wayde Dazelle,
  • Megan Ebner,
  • Jamil Kazma,
  • Homa Ahmadzia
Wayde Dazelle
The George Washington University School of Medicine and Health Sciences
Author Profile
Megan Ebner
The George Washington University School of Medicine and Health Sciences
Author Profile
Jamil Kazma
The George Washington University School of Medicine and Health Sciences
Author Profile
Homa Ahmadzia
The George Washington University School of Medicine and Health Sciences
Author Profile

Abstract

Objectives: To estimate the cost-effectiveness of alternative risk-dictated strategies utilizing prophylactic tranexamic acid (TXA) for the prevention of postpartum hemorrhage (PPH).
Study Design: We constructed a microsimulation-based Markov decision-analytic model estimating the cost-effectiveness of three alternative risk-dictated strategies for TXA prophylaxis versus the status quo (no TXA) in a cohort of 3.8 million pregnant women delivering in the United States. Each strategy differentially modified risk-specific hemorrhage probabilities by preliminary estimates of TXA’s prophylactic efficacy. Outcome measures included incremental costs, quality-adjusted life-years (QALYs), and adverse maternal outcomes averted. Costs and benefits were considered from the healthcare system and societal perspectives over a lifetime time horizon.  
Results: All TXA strategies were dominant versus the status quo, implying that they were more effective while also being cost-saving. Providing TXA to all delivering women irrespective of hemorrhage risk produced the most favorable results overall, with estimated cost savings greater than $670 million and up to 149,505 PPH cases, 2,933 hysterectomies, and 70 maternal deaths averted, per annual cohort. Threshold analysis suggested that TXA is likely to be cost-saving for health systems at costs below $184 per gram.  
Conclusions: Our findings suggest that routine prophylaxis with TXA would likely result in substantial cost-savings and reductions in adverse maternal outcomes in this context. The integrity of this conclusion is maintained across all risk-dictated strategies, even when the cost of TXA is significantly higher than what is supported in the literature.